NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Hangzhou DAC Biotechnology Co., Ltd.

Hangzhou DAC Biotechnology Co., Ltd.

Private
HangzhouHealthcare & Life Scienceshttp://dacbiotech.com/

Last Round

Strategic

Jun 1, 2022

Est. Valuation

$52.25M

Total Funding Raised

$322.77M

Company Overview

Hangzhou DAC Biotechnology Co., Ltd. is a biopharmaceutical company that specializes in the research, development, and production of monoclonal antibody-drug conjugates (ADCs) for the treatment of advanced cancers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Keywords

antibody-drug conjugateADCtargeted cancer therapyoncology drug developmentbiopharmaceuticallinker technologycytotoxic payloadclinical-stage biotechantibody discoveryprecision medicinedrug licensingpreclinical evaluationnext-gen oncologybiotech pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Hangzhou DAC Biotechnology Co., Ltd. Comps

Public and private peers based on sector, stage, and business model.

Hangzhou DAC Biotechnology Co., Ltd. comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Hangzhou DAC Biotechnology Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicJun 1, 2022
Series CMay 10, 2021
Series CMar 1, 2021
Series BSep 1, 2019
Series AMay 1, 2017
Pre Seed
Nov 27, 2015

Key People

Founding team and executive leadership

Robert Zhao

Chief Executive Officer

Executive Team

Hangzhou DAC Biotechnology Co., Ltd. Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 1, 2022

    Led by Johnson & Johnson Innovation - JJDC, Inc.

  • May 10, 2021

    $156M round led by CDG Capital and Chenling Capital.

Hangzhou DAC Biotechnology Co., Ltd. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Hangzhou DAC Biotechnology Co., Ltd. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Hangzhou DAC Biotechnology Co., Ltd.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersHangzhou
Employee Range4
Year Founded2012
Last FundingJun 1, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.